Brought to you by 
Galera Therapeutics brings in $11mm in Series A funds
03 Jan 2013
Executive Summary
Galera Therapeutics Inc. (developing drugs that target the oxygen metabolic pathways) has raised $11mm through its Series A round. New Enterprise Associates and Novartis Venture Funds co-led the round and take seats on the board. Correlation Ventures and one unnamed buyer also participated.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galera Therapeutics brings in $11mm in Series A funds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice